A Novel Nanomicellar Combination of Fenretinide and Lenalidomide Shows Marked Antitumor Activity in a Neuroblastoma Xenograft Model

PURPOSE: Currently >50% of high-risk neuroblastoma (NB) patients, despite intensive therapy and initial partial or complete response, develop recurrent NB due to the persistence of minimal residual disease (MRD) that is resistant to conventional antitumor drugs. Indeed, their low therapeutic inde...

Descrición completa

Gardado en:
Detalles Bibliográficos
Publicado en:Drug Des Devel Ther
Main Authors: Orienti, Isabella, Nguyen, Ferro, Guan, Peng, Kolla, Venkatadri, Calonghi, Natalia, Farruggia, Giovanna, Chorny, Michael, Brodeur, Garrett M
Formato: Artigo
Idioma:Inglês
Publicado: Dove 2019
Assuntos:
Original Research
Acceso en liña:https://ncbi.nlm.nih.gov/pmc/articles/PMC6930389/
https://ncbi.nlm.nih.gov/pubmed/31908416
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.2147/DDDT.S221909
Tags: Engadir etiqueta
Sen Etiquetas, Sexa o primeiro en etiquetar este rexistro!

Títulos similares